Abstract. Lymphomatoid granulomatosis (LYG) is a rare tumor with unknown etiology. Specific etiological factors for LYG are also unknown, although previous data indicates that LYG is an Epstein-Barr virus-associated B-cell proliferation associated with an exuberant T-cell reaction. According to the 2008 WHO classification, LYG is characterized by B-cell proliferation of B-lymphoma cells. Generally, treatment options for LYG are similar to those for diffuse large B-cell lymphoma. Unfortunately, LYG is a chemotherapy-resistant disease in certain patients and has a poor prognosis. The current study presents the case of a 19-year-old male patient with pulmonary LYG. The patient exhibited progressive disease following one cycle of chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone, and nodular lesions in the brain were diagnosed. Radiotherapy was delivered to the whole brain, however, this treatment did not prevent progression of the disease and the patient succumbed three months after initial presentation. An overview of the literature with regard to the etiology, clinical features, diagnosis and treatment options for LYG is also presented in the current case study.

Introduction

Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-associated disorder and is considered part of the spectrum of lymphoproliferative disorders. While commonly presenting with multiple lung nodules, in occasional cases, atypical patterns can be observed radiographically. Specific systemic manifestations can occur, including fever, weight loss, skin lesions and the involvement of other organs (1). The clinical presentation of LYG can mimic infectious diseases (including tuberculosis), vasculitis or metastatic malignancies. According to the 2008 WHO classification, LYG is characterized by the proliferation of B-lymphoma cells (2). Patients may present with non-specific neurological symptoms, including seizures and incontinence (3). In order to make a definitive diagnosis, biopsies, pathological examinations and immunohistochemical analyses must be performed. In the current study, an overview of the literature in reference to the etiology, clinical features, diagnosis and treatment options for LYG is presented. Patient provided written informed consent.

Case report

A 19-year-old male was presented to the pulmonary clinic of the People's hospital of Shenzhen University (Shenzhen, China) with chills, a fever, mild intermittent dry coughing, night sweats and fatigue that had lasted 7 days. One month prior to this presentation, the illness began with a low fever, mild coughing and fatigue. The patient was treated symptomatically for a presumed upper-respiratory viral infection. The patient had fevers as high as 40.2˚C and had no significant exposure history. The patient had no risk factors for human immunodeficiency virus (HIV) infection, and was an ex-smoker. Upon presentation, the patient did not experience respiratory distress and the vital signs were as follows: Temperature, 40.2˚C; heart rate, 110 beats/min; respiratory rate, 24 breaths/min; and blood pressure, 120/70 mmHg. Oxygen saturation (measured via digital pulse oximetry) was 95% while breathing ambient air. The skin was diaphoretic and there were no palpable lymph nodes in all areas. Chest, cardiac, abdominal and skin examinations did not reveal abnormalities. On lung auscultation, breath sounds were diminished over the lower left lung, and there were no crackles or rales on either side. A neurological examination revealed no focal defect.

The white blood cell count of the patient was 4.7x10^3/dl and the hemoglobin level was 13.0 g/dl. Serum electrolyte levels and liver and renal function were normal. Spirometry values and the erythrocyte sedimentation rate (ESR; 7 mm/h) were normal. Routine blood and sputum cultures for detection of acid-fast bacteria were negative. Serological tests revealed that there was no infection with hepatitis B virus, hepatitis C virus, HIV and tubercle bacillus. Computed tomography (CT)
imaging demonstrated bilateral pulmonary multiple round nodules, predominantly in the lower lung fields, along the bronchoalveolar structures (Fig. 1). There was no mediastinal or hilar lymph node enlargement. F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) revealed multiple hypermetabolic pulmonary nodules in the lungs, predominantly in the lower lobes [maximum standard uptake value (SUVmax), 3.3-7.8; Fig. 2). Splenomegaly was observed and the SUVmax was 12.4 in the PET/CT image. The CT-guided transthoracic biopsy revealed inflammatory cells and large coagulated necrotic tissue. The patient consented to the removal of a thoracoscopic biopsy, which revealed an angiocentric and angiodestructive infiltrate of lymphoid cells in the vascular wall, with surrounding infarct-like tissue necrosis (Fig. 3). Immunohistochemical staining revealed that the lymphoid infiltrate consisted of a mixture of cells expressing cluster of differentiation (CD)45RO, CD3, CD20 and CD79α.

Furthermore, in situ hybridization for the detection of EBV was strongly positive (Fig. 3). A diagnosis of LYG was finally established.

The patient received chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). The body temperature was normal during the chemotherapy. However, only two days subsequent to the end of chemotherapy, the patient developed a generalized tonic-clonic seizure and fever. T1- and T2-weighted magnetic resonance (MR) images revealed multiple irregular and nodular lesions, with peripheral edema in the bilateral parietal lobe and the left cornu occipitale of the substantia alba (Fig. 4). Central nervous system
(CNS) involvement was considered. Therefore, the patient received whole brain irradiation with a total dose of 30 Gy in 10 fractions. This treatment did not halt the generalized tonic-clonic seizure, while the coughing, shortness of breath and hyperpyrexia continued. A chest-CT revealed a left-sided pleural effusion, lobe inferior pulmonis atelectasis and small amounts of pericardial effusion. The patient received 2 l/min oxygen by nasal canula. Subsequently, the patient developed rapid pulmonary failure, and succumbed ~3 months after presentation due to progressive pulmonary and CNS disease.

Discussion

LYG is a rare lymphoproliferative disease. Liebow et al designated the term ‘lymphomatoid granulomatosis’ almost 40 years ago, as an angiocentric and angiodestructive lymphoreticular proliferative and granulomatous disease with EBV infection, lung lesions and a poor outcome (4). The first description of the disease was followed by several reports about the nature, histopathology and treatment of LYG. The following is an overview of this literature.

LYG has an increased male predilection, with male-female ratios ranging between 2:1 and 3:1. Generally, patients are between 40 and 60 years old (5). LYG frequently presents as a systemic disease, usually with prominent pulmonary sites. Other sites can also be involved, including the skin, CNS, kidney, liver, upper respiratory tract and gastrointestinal tract. Lymph node and spleen involvement are less common (7-8%). Constitutional symptoms, including weight loss, fatigue, sweating and chills, are typical (6). Local symptoms include coughing, shortness of breath and chest pain, while almost one-third of patients develop neurological symptoms, including confusion, ataxia, hemiparesis or seizures, mainly due to lesions in the CNS. Cranial nerve palsies and peripheral polyneuropathy have also been described in 7% of cases (7-10).

Chest X-rays reveal bilateral lesions in 71-90% of patients. The most frequent observations are multiple nodules or masses with poorly defined margins, whereas reticular or nodular infiltrates are less often described. Cavitations or solitary masses are rarely presented. Pleural effusions (25%) are usually small and present as costophrenic angle blunting. Mediastinal lymphadenopathy is visible on CT in 60% of patients, and nodules are characteristically observed alongside bronchovascular structures and interlobular septa (11,12). The application of FDG-PET for tumor imaging has proved to be highly useful for the diagnosis of primary lung tumors. If LYG is radiologically proven to involve the CNS, this is shown as multiple punctate and linear enhancement on CT and MR images, representing lesions in perivascular tissue and the walls of small blood vessels (13). Patsalides et al (14) conducted a comprehensive retrospective analysis of the MRI results of 25 patients with LYG and found a wide spectrum of CNS lesions in 52% (13/25) of the patients. In the most frequent cases, the patients presented with multifocal intraparenchymal brain lesions, which exhibited punctate or linear enhancement (n=7), followed by leptomeningeal and cranial nerve involvement (n=6).

LYG is similar to Wegener’s granulomatosis in clinical features and imaging, including pulmonary manifestations and the systemic nature. The differential diagnosis includes tuberculosis, granulomatosis, lung cancer and inflammatory pseudotumors. The prognosis of LYG is extremely variable, ranging from extremely good in the cases of spontaneous resolution, to rapidly fatal. The median survival time ranges between 14 months and 4 years, and the 5-year mortality rate is 60-90%. In total, 94% of mortalities occur in the first 36 months following diagnosis (15-17). Certain studies indicate that leucopenia, fever, anergy in reaction to common skin test antigens, a young age and localization in the CNS are poor prognostic signs (7,8,18). A biopsy must be taken to make a definitive diagnosis. Transbronchial biopsy is not recommended, as it is diagnostic in only 27% of cases, while open lung biopsy specimens are uniformly positive (19).

As LYG is a rare disease, a standard treatment paradigm has not yet been established, and consequently, the treatment of LYG remains a challenge. Certain patients have self-limiting disease, a number are treated with corticosteroids, either as single agent or combined with cyclophosphamide, and certain patients are treated with another chemotherapy, including CHOP or COP regimens, depending on severity at presentation. LYG responds poorly to conventional chemotherapy, and no significant differences have been identified between the regimens, while radiotherapy has also been used for CNS and orbital localizations (7,20,21). Rituximab-CHOP, or other similar regimens, are usually recommended for treatment of grade 3 LYG due to the high rate of rapid progression into EBV-positive large B-cell lymphoma (22,23). Several case studies have been published in which treatments with interferon α-2b, with or without autologous stem cell transplantation (24-26), and prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, mechloethamine, vincristine, and procarbazine or cyclosporin-A were presented (27). For the patient in the present case study, CHOP chemotherapy and radiotherapy failed, and rapid progressive disease was observed in the CNS. The present case demonstrated that LYG is a chemotherapy-resistant disease in certain patients. LYG remains rarely recognized as an entity, and proper diagnosis and treatment remain a challenge.

Acknowledgements

This project was supported by the Natural Science Foundation of China (no. 30900597) and the Science Foundation of Hubei Health Department (no. JX6B08).

References

1. de Boysson H and Geffray L: Lymphomatoid granulomatosis. Rev Med Interne 34: 349-357, 2013 (In French).
2. Vardiman JW: The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms. Chem Biol Interact 184: 16-20, 2010.
3. Dister F and Ghaye B: Lymphomatoid granulomatosis. JBR-BTR 95: 140-141, 2012.
4. Liebow AA, Carrington CR and Friedman PJ: Lymphomatoid granulomatosis. Hum Pathol 3: 457-558, 1972.
5. Mazzie JP, Price AP, Khullar P, et al: Lymphomatoid granulomatosis in a pediatric patient. Clin Imaging 28: 209-213, 2004.
6. Lundell RB, Weening RH and Gibson LE: Lymphomatoid granulomatosis. Cancer Treat Res 142: 265-272, 2008.
7. Katzstein AL, Carrington CR and Liebow AA: Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer 43: 360-373, 1979.
8. Fauci AS, Haynes BF, Costa J, Katz P and Wolff SM: Lymphomatoid granulomatosis. Prospective clinical and therapeutic experience over 10 years. N Engl J Med 306: 68-74, 1982.
9. Koss MN, Hochholzer L, Langloss JM, Wehunt WD, Lazarus AA and Nichols PW: Lymphomatoid granulomatosis: a clinicopathologic study of 42 patients. Pathology 18: 283-288, 1986.
10. Katzenstein AL and Peiper SC: Detection of Epstein-Barr virus genomes in lymphomatoid granulomatosis: analysis of 29 cases by the polymerase chain reaction technique. Mod Pathol 3: 435-441, 1990.
11. Wechsler RJ, Steiner RM, Israel HL and Patchefsky AS: Chest radiograph in lymphomatoid granulomatosis: comparison with Wegener granulomatosis. AJR Am J Roentgenol 142: 79-83, 1984.
12. Lee JS, Tuder R and Lynch DA: Lymphomatoid granulomatosis: radiologic features and pathologic correlations. AJR Am J Roentgenol 175: 1335-1339, 2000.
13. Tateishi U, Terae S, Ogata A, et al: MR imaging of the brain in lymphomatoid granulomatosis. AJNR Am J Neuroradiol 22: 1283-1290, 2001.
14. Patsalides AD, Atac G, Hedge U, et al: Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging. Radiology 237: 265-273, 2005.
15. Jaffe ES and Wilson WH: Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv 30: 233-248, 1997.
16. Cadranel J, Wislez M and Antoine M: Primary pulmonary lymphoma. Eur Respir J 20: 750-762, 2002.
17. Katherine Martin L, Porcu P, Baiocchi RA, Erter JW and Chaudhury AR: Primary central nervous system lymphomatoid granulomatosis in a patient receiving azathioprine therapy. Clin Adv Hematol Oncol 7: 65-68, 2009.
18. Wilson WH, Kingma DW, Raffeld M, Wittes RE and Jaffe ES: Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood 87: 4531-4537, 1996.
19. Pisani RJ and DeRemee RA: Clinical implications of the histopathologic diagnosis of pulmonary lymphomatoid granulomatosis. Mayo Clin Proc 65: 151-163, 1990.
20. Sordillo PP, Epremian B, Koziner B, Lacher M and Lieberman P: Lymphomatoid granulomatosis: an analysis of clinical and immunologic characteristics. Cancer 49: 2070-2076, 1982.
21. Petrella TM, Walker JR, Jones GW and Leber R: Radiotherapy to control CNS lymphomatoid granulomatosis: a case report and review of the literature. Am J Hematol 62: 239-241, 1999.
22. Rao R, Vugman G, Leslie WT, Loew J and Venugopal P: Lymphomatoid granulomatosis treated with rituximab and chemotherapy. Clin Adv Hematol Oncol 1: 658-660, 2003.
23. Ishiura H, Morikawa M, Hamada M, et al: Lymphomatoid granulomatosis involving central nervous system successfully treated with rituximab alone. Arch Neurol 65: 662-665, 2008.
24. Richter C, Schnabel A, Müller KM, Reuter M, Schuster P and Gross WL: Lymphomatoid granulomatosis - remission induction with interferon-alpha 2b. Dtsch Med Wochenschr 122: 1106-1110, 1997 (In German).
25. Lemieux J, Bernier V, Martel N and Delage R: Autologous hematopoietic stem cell transplantation for refractory lymphomatoid granulomatosis. Hematology 7: 355-358, 2002.
26. Johnston A, Coyle L and Nevell D: Prolonged remission of refractory lymphomatoid granulomatosis after autologous hematopoietic stem cell transplantation with post-transplantation maintenance interferon. Leuk Lymphoma 47: 323-328, 2006.
27. Raez LE, Temple JD and Saldana M: Successful treatment of lymphomatoid granulomatosis using cyclosporin-A after failure of intensive chemotherapy. Am J Hematol 53: 192-195, 1996.